• A Glimpse Into Thailand’s Ongoing Life Sciences Transformation
    A Glimpse Into Thailand’s Ongoing Life Sciences Transformation

    During my visit to Thailand, I was privy, not only to the particularly innovative research goals being pursued, but also to a number of challenges the country has recognized and hopes to address within the next few years to encourage a stronger, more diverse industry.

What Thailand Revealed About U.S. Pharma R&D

A few weeks ago, I was invited by the Thailand Board of Investment to attend a media trip to learn about the country’s budding life sciences industry. Entering Thailand, a country in which the government is pushing more investment and education in the sciences, was even more striking and meaningful to me given the current scientific climate in the U.S.

Top 5 Biosimilar Developments Of 2016

In the spirit of this list-making season, I compiled what I thought were the five most important biosimilar-related triumphs in the past year. Many of these events were widely covered by the media and will play an influential role in how the biosimilar industry unfolds through 2017 and beyond.

Are You The Future of Pharmaceutical Development?

Pfizer's Bernie Huyghe and ADC Therapeutics' Michael Mulkerrin get bushwhacked with this question in a public forum. Their open replies will help each one of you to your own personal assessment. Be prepared for some soul searching.

The Case For Moving The EMA To Ireland

Relocating an organization as large as the EMA, which employs upwards of 1,000 people in London, will be no easy feat. As such, IDA Ireland, an agency that supports companies in Ireland and promotes foreign direct investments in the country, is working to compile information on why Ireland would be a good location for the EMA.

More From Our Editors


  • How To Successfully Manage Packaging And Labeling During Pharma Product Launches
    How To Successfully Manage Packaging And Labeling During Pharma Product Launches

    If you are charged with any of the tasks that lead to a successful product launch in the pharmaceutical industry, you know how critical it is to execute a multitude of steps successfully. Among these are agreement by marketing on the look and design of the campaign, completion of clinical trials, project management, testing of active pharmaceutical ingredients, the completion of a trial production batch, receipt of all materials at the production site, production scheduling, regulatory agency submissions, trademark registration, and a host of others.

  • 10 Steps To Develop A Sustainable Training Program For Pharma Operations
    10 Steps To Develop A Sustainable Training Program For Pharma Operations

    Investing in training for employees in the life sciences and biopharmaceuticals industries generates quantifiable returns that go far beyond simply imparting specific, task-oriented knowledge. For example, effective and thoughtfully planned onboarding and sustainable training are key elements in attaining a culture of quality throughout the organization. Furthermore, inadequate training contributes to process and product variability.

  • Designing An Environmental Monitoring Program For Non-Sterile Manufacturing: A Risk-Based Approach
    Designing An Environmental Monitoring Program For Non-Sterile Manufacturing: A Risk-Based Approach

    Microbial control for non-sterile manufacturing helps to ensure the safety and efficacy of pharmaceuticals. Products that are compromised with excessive amounts of microorganisms, specified microorganisms, or objectionable microorganisms may not be effective or could be dangerous to consumers. Unfortunately, the regulations governing non-sterile manufacturing are not as clear or as abundant as those for sterile manufacturing. This leads many manufacturers to utilize risk assessment analysis tools to adapt portions of sterile manufacturing guidelines when developing environmental monitoring programs for non-sterile environments.

  • 5 Steps To Set Effective Goals For A Life Science Consultant

    There is a trend within the pharmaceutical, biopharmaceutical, medical device, and vaccine industries to hire more consultants, leading to a staffing ratio that can be up to 50 percent consultants to staff for small to large capital projects.

  • “Human Error” Deviations: How You Can Stop Creating (Most Of) Them

    In the time it takes you to read this article, the industry will generate (conservatively) about 115 new process deviations, and about 65 of them will be misclassified as having something related to “human error” as either the principal causal factor or one of the proximal causal factors.

More From Guest Contributors


  • Achieving Global Certification In Food Safety & Quality

    What is the only thing on retailers and manufacturers’ minds more than safety? The economy and consumer demand, which translates to profitability. In a competitive world market, made even tougher by recent legislation in major markets such as the U.S. and China to reassure consumers, producers at every point in the supply chain are carefully watching margins while seeking new strategies to protect market share.

  • Improve The Reliability Of Your Process Models: A Holistic Approach For Chemical Engineers

    Chemical engineering is a discipline that to a certain degree relies on deterministic or first principle models. By Dr. Frank Westad, Chief Scientific Officer, CAMO Software

More Pharma Onine White Papers


More Industry Insights


Best Practices in CMC Dossier Preparation – Facing Tough Challenges October 19, 2017
1pm-2:30pm EDT, Online Training
25th World Cancer Conference October 19 - 21, 2017
Immuno-Oncology: An Introductory Overview October 19, 2017
Newark, NJ
DMC Optimization Summit October 19 - 20, 2017
Philadelphia, PA
More Industry Events